DeepMed Research

GILEAD SCIENCES SL

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1994-01-01

Employees: -

Market Cap: $95.8B

Website: http://www.gilead.com/about/worldwide-operations/europe/spain

Clinical Trials

Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection

Phase 2

Completed

Conditions: HCV Infection

Interventions: Drug: LDV/SOF
Drug: Placebo to match RBV
Drug: RBV
Drug: Placebo to match LDV/SOF

First Posted Date: 2013-10-18

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 155

Registration Number: NCT01965535

SOF (Sovaldi®) +RBV for 16 or 24 Weeks and SOF+RBV+Peg-IFN for 12 Weeks in Adults With Genotype 2 or 3 Chronic HCV Infection

Phase 3

Completed

Conditions: Hepatitis C

Interventions: Drug: SOF
Drug: RBV
Drug: Peg-IFN

First Posted Date: 2013-10-14

Last Posted Date: 2017-06-20

Lead Sponsor: Gilead Sciences

Target Recruit Count: 601

Registration Number: NCT01962441

Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

Phase 2

Completed

Conditions: HCV Infection

Interventions: Drug: LDV/SOF
Drug: SOF
Drug: RBV

First Posted Date: 2013-10-09

Last Posted Date: 2018-08-08

Lead Sponsor: Gilead Sciences

Target Recruit Count: 38

Registration Number: NCT01958281

Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer

Phase 3

Terminated

Conditions: Metastatic Pancreatic Cancer
Pancreatic Cancer

Interventions: Drug: IMMU-107
Drug: placebo
Drug: Gemcitabine

First Posted Date: 2013-10-08

Last Posted Date: 2021-08-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 334

Registration Number: NCT01956812

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
University of Pennsylvania Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Pittsburgh Medical Center/Hillman Cancer Center, Pittsburgh, Pennsylvania, United States

and more 60 locations

Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B

Phase 2

Completed

Conditions: Chronic HBV Infection

Interventions: Biological: GS-4774
Drug: OAV Regimen

First Posted Date: 2013-09-17

Last Posted Date: 2019-11-01

Lead Sponsor: Gilead Sciences

Target Recruit Count: 178

Registration Number: NCT01943799

Locations: 🇺🇸
Digestive Disease Associates, PA, Baltimore, Maryland, United States
🇺🇸
St.Louis University, Saint Louis, Missouri, United States
🇺🇸
Medical Pro-care, Flushing, New York, United States

and more 12 locations

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen

Phase 3

Completed

Conditions: HBeAg-positive Chronic Hepatitis B

Interventions: Drug: TDF
Drug: TAF
Drug: TDF Placebo
Drug: TAF Placebo

First Posted Date: 2013-09-12

Last Posted Date: 2023-10-10

Lead Sponsor: Gilead Sciences

Target Recruit Count: 875

Registration Number: NCT01940471

Locations: 🇮🇳
Gleneagles Global Hospital, Hyderabad, India
🇨🇦
Gordon and Leslie Diamond Health Care Centre, Vancouver, British Columbia, Canada
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States

and more 155 locations

Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Negative for Hepatitis B e Antigen

Phase 3

Completed

Conditions: HBeAg-negative Chronic Hepatitis B

Interventions: Drug: TAF
Drug: TDF
Drug: TDF Placebo
Drug: TAF Placebo

First Posted Date: 2013-09-12

Last Posted Date: 2023-09-25

Lead Sponsor: Gilead Sciences

Target Recruit Count: 426

Registration Number: NCT01940341

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇷🇴
Spitatul Clinic de Boli Infectioase Constanta, Constanta, Romania
🇬🇧
Barts and The London NHS Trust Royal London Hospital, London, United Kingdom

and more 102 locations

Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant

Phase 2

Completed

Conditions: Chronic HCV Infection

Interventions: Drug: LDV/SOF
Drug: RBV

First Posted Date: 2013-09-10

Last Posted Date: 2018-11-16

Lead Sponsor: Gilead Sciences

Target Recruit Count: 339

Registration Number: NCT01938430

Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: LDV/SOF

First Posted Date: 2013-08-19

Last Posted Date: 2018-11-19

Lead Sponsor: Gilead Sciences

Target Recruit Count: 5

Registration Number: NCT01924949

Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants

Phase 2

Terminated

Conditions: Acquired Immune Deficiency Syndrome (AIDS)
HIV Infections

Interventions: Drug: EVG
Drug: Background regimen

First Posted Date: 2013-08-15

Last Posted Date: 2018-08-09

Lead Sponsor: Gilead Sciences

Target Recruit Count: 31

Registration Number: NCT01923311

Locations: 🇿🇦
Be Part Yoluntu Centre, Cape Town, South Africa
🇮🇹
Universita degli Studi di Pavia - Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
🇺🇬
Joint Clinical Research Centre, Kampala, Uganda

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy